Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
about
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerScavenger Receptors: Emerging Roles in Cancer Biology and ImmunologySynthetic high-density lipoprotein-like nanoparticles as cancer therapyAbiraterone in the treatment of metastatic castration-resistant prostate cancerTargeting SR-BI for Cancer Diagnostics, Imaging and TherapyTargeting the SR-B1 Receptor as a Gateway for Cancer Therapy and ImagingHigh-Density Lipoproteins: Nature's Multifunctional NanoparticlesQuantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progressionApolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In VivoThe importance of LDL and cholesterol metabolism for prostate epithelial cell growthPartners in crime: deregulation of AR activity and androgen synthesis in prostate cancerBiomimetic high density lipoprotein nanoparticles for nucleic acid delivery.Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.Update on current and potential nanoparticle cancer therapiesNew frontiers in androgen biosynthesis and metabolism.Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.The complex interplay between cholesterol and prostate malignancy.Berberine suppresses androgen receptor signaling in prostate cancer.Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate CancerEpidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes.Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).Synthetic high-density lipoprotein-like nanoparticles for cancer therapyLipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1.Biomimetic, synthetic HDL nanostructures for lymphoma.New players for advanced prostate cancer and the rationalisation of insulin-sensitising medicationPerspectives on treatment of metastatic castration-resistant prostate cancer.Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells.Cancer prevention and therapy through the modulation of the tumor microenvironment.The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer by controlling a program of ligand dependent SXR target genes.The anticancer effect of fucoidan in PC-3 prostate cancer cells.Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma."Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.
P2860
Q26739708-F8C66DB5-9C6A-4762-BC5E-69C11AC2BB05Q26799114-6AA5C060-7DA6-4D59-BB88-7560245E7D20Q26825009-45BD1EA2-66A9-4256-B5A1-598D8DFD4010Q26853635-5C1630B4-A1D3-48CC-BBD2-D93F829BE2F6Q28066708-993F88AD-D1DD-4E5D-8CA1-915FE9EE2AC2Q28070244-7908D5E8-19C9-4D93-BDCE-FAC238249911Q28077290-1A43BC21-EE9F-45F7-BB29-56586D5DA3B0Q28286300-C7B27BC6-AED7-4F64-BFF1-30848F829233Q28550931-9A5C833A-A2B8-4021-A731-D9EC3350188CQ28727920-7655D98E-5628-4B27-AF8E-BF8A93F5E7C5Q33823702-2E6763D5-2127-4926-B75F-B485FA8510DDQ33830955-5751FF6C-D174-40C8-ACC2-41AF25A4023CQ33856101-48B432C0-91DF-413A-A630-AB36E6A00AA4Q33874239-6C6AA4E6-E1EE-4106-A780-05CEA5130079Q34100727-89C24DED-233E-47DF-AA72-5996B56EEF00Q34137546-4A74C732-6BAE-4D30-8A6B-933FC4F84899Q34548388-3B0C7A7A-4DD7-4D99-8211-A4AF01F09488Q34586300-A7A02D78-A527-44C1-A6D7-A27415A2ECFEQ34763617-35A7038C-43A5-466D-84DB-C915B0011DC4Q35137013-3412E6A3-5737-4D6D-BC95-48D6205CF64EQ35159508-1D3B83DA-3005-460A-86A4-688F4C0D333AQ35223874-45DA769A-41BB-4F07-8BD6-06B3910917A2Q35532230-6D02B311-747D-40F0-A74A-B5D8219A1E55Q35683332-D2A8FE32-A6E9-456D-9BCD-C7AA78BF098EQ35882782-8456F514-116F-45C2-B93B-E7964F12CD6BQ36010700-BF4715F0-018F-437A-92B2-4D83BDA76156Q36055229-4594049E-F11B-4D64-ADA0-2051AC440DDBQ36264073-AF0DB9E4-543F-4237-AD66-A9584B3CD800Q36323141-65D64A72-FDCB-4A21-B7D7-03188127B555Q36569962-9A21AC68-E771-4257-941A-061761D68BA1Q36586161-03CEA438-BD98-4D3B-85EE-BE67EB89EBC5Q36616904-41560E2E-0D6D-46BE-A8A8-ECB2F0ABCF12Q36734036-4F8005D0-F784-4F88-ACED-5C29A0A75504Q36871685-1D43694F-7DE3-4032-B623-74BE6CEDD186Q36873039-51178185-9307-4D96-AFD2-0952878C28A0Q37058267-F49FF5C9-69BA-416D-AD61-31A4AA7833A2Q37138526-330F6F6F-8705-4640-99D6-E3E376990B50Q37155606-3C9B1905-458F-44EA-8A22-2AB221687311Q37475635-09F2A9D8-BC79-47E5-BD0E-50FBDCA69BE3Q37804661-C3DBBA40-9645-401B-8AC1-A17A59BD840E
P2860
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Alterations in cholesterol reg ...... er in a mouse xenograft model.
@en
Alterations in cholesterol reg ...... er in a mouse xenograft model.
@nl
type
label
Alterations in cholesterol reg ...... er in a mouse xenograft model.
@en
Alterations in cholesterol reg ...... er in a mouse xenograft model.
@nl
prefLabel
Alterations in cholesterol reg ...... er in a mouse xenograft model.
@en
Alterations in cholesterol reg ...... er in a mouse xenograft model.
@nl
P2093
P2860
P356
P1433
P1476
Alterations in cholesterol reg ...... er in a mouse xenograft model.
@en
P2093
Alexis L Twiddy
Carlos G Leon
Colleen C Nelson
Emma S Guns
Hans H Adomat
Jennifer A Locke
Kishor M Wasan
Rachel D Neumann
Susan L Etinger
P2860
P304
P356
10.1002/PROS.21072
P577
2010-03-01T00:00:00Z